Future Science Group
Browse
Supplementary information.docx (15.93 kB)
Download file

Supplementary Info – Biomarker subset analysis of a Phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC

Download (15.93 kB)
dataset
posted on 2022-02-04, 08:53 authored by Figshare Future Science GroupFigshare Future Science Group, Jun Zhao, Hua Bai, Xin Wang, Yuyan Wang, Jianchun Duan, Hanxiao Chen, Zhiyi Xue, Yahui Tian, Agnieszka Cseh, Dennis Chin-Lun Huang, Yi-Long Wu, Jie Wang

Safety analyses – Methods, Safety outcomes

Funding

Boehringer Ingelheim International GmbH

History

Usage metrics

    Future OncologyFuture Oncology

    Categories

    Keywords

    EGFR-mutated NSCLCAfatinibChinaPlasma biopsycfDNAEGFR TKIbiomarkersCancer Therapy (excl. Chemotherapy and Radiation Therapy)Solid Tumours

    Licence

    CC BY-NC-ND 4.0

    Exports